Proton pump inhibitors regulate metabolic profile and glycaemic indices in patients with type 2 diabetes mellitus: A rising dawn of a new therapeutic concept.

ABSTRACT

OBJECTIVE: To evaluate the effect of proton pump inhibitors on glycaemic indices in patients with type 2 diabetes mellitus. METHODS: The case-control study was conducted at the National Diabetes Centre, Mustansiriyah University, Baghdad, Iraq, from January to April 2018, and comprised type 2 diabetes patients and non-diabetic healthy controls. The subjects were divided into three groups Group A had controls on proton pump inhibitors; Group B had patients treated with metformin 850 g/day; and Group C had patients treated with metformin 850 g/day plus proton pump inhibitors. Gastrin serum levels, lipid profile, glycaemic indices and blood pressure changes were measured in the groups. Data was analysed using SPSS 20. RESULTS: Of the 100 subjects, 60(60%) were patients with a mean age of 54.98}4.22 years, while40(40%) were controls with a mean age of 50.69}4.34 years. Group A had 40(40%) subjects, while Group B and Group C had 30(30%) each. Proton pump inhibitors improved glycaemic indices and lipid profile in the patients 9p<0.05) while increasing gastrin serum levels which were significantly correlated with reduction in glycated haemoglobin, fasting blood glucose and augmentation of ß-cell function (p<0.05 each). CONCLUSIONS: Proton pump inhibitors improved glycemic indices and metabolic profile in type 2 diabetes patients via augmentation of gastrin serum levels.